Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,445 total articles
BriaCell Therapeutics has received FDA clearance for its Investigational New Drug application, allowing the initiation of a Phase 1/2a clinical study of its next-generation personalized immunotherapy, Bria-PROS+, targeting prostate cancer. The therapy incorporates multiple immune activation components designed to enhance clinical efficacy and has p…
Medline Inc. reported an 11.6% increase in second-quarter net sales to $7.7 billion and a 13.4% increase in Adjusted EBITDA to $1.1 billion for Q2 2026, driven by strong organic sales growth and new customer signings. However, net income decreased by 58.3% to $139 million due to a $336 million loss from a fire at the Tracy, California distribution …
Bioventus Inc. announced its second quarter 2026 financial results, reporting a 4% increase in revenue to $153.2 million, driven largely by double-digit growth in Pain Treatments. GAAP earnings improved markedly to $0.47 per diluted share from $0.11 in the prior year, supported by the removal of a $24.6 million valuation allowance on deferred tax a…
Stardust Power Inc. announced a non-binding Letter of Intent with Charge CCCV LLC (C4V) to supply battery-grade lithium carbonate from its Muskogee, Oklahoma refinery. The agreement outlines phased demand projections through 2030, reinforcing Stardust's role in the growing U.S. domestic battery supply chain and supporting C4V's expanding battery ma…
EVgo Inc. announced its second quarter 2026 financial results, highlighting a 19% year-over-year increase in charging network revenue to $61 million and a 24% increase in operational charging stalls. The company signed a significant agreement with Tesla to deploy EVgo Superchargers, enhancing its fast-charging infrastructure across the U.S. Despite…
Holley Performance Brands announced a 3.2% increase in net sales to $172 million for Q2 2026, driven by growth in three of its four business segments. Despite reporting a net loss of $2.4 million due to a $28.3 million loss on sale of non-core assets, adjusted net income and free cash flow increased significantly. The company continued reducing deb…
Origin Agritech Ltd. (NASDAQ: SEED) has obtained exclusive commercial rights to Zhongdan 6202, a top-tier early-maturing corn hybrid developed under China's 14th Five-Year Plan. This variety addresses critical needs in the northeast Chinese corn market by enabling mechanized harvest with high yields, disease resistance, and cold tolerance. Origin p…
Immuneering Corporation reported strong second quarter 2026 results highlighted by promising Phase 2a data showing a median overall survival of 17.3 months for pancreatic cancer patients treated with atebimetinib combined with chemotherapy. The company is progressing with its Phase 3 MAPKeeper 301 trial, dosing patients across over 30 locations. Ad…
Palvella Therapeutics, a clinical-stage biopharmaceutical company focused on rare skin diseases and vascular malformations, announced that its CEO Wes Kaupinen will participate in a fireside chat at the upcoming Canaccord Genuity Growth Conference. The company highlighted its pipeline, including its lead product candidate QTORIN™ 3.9% rapamycin gel…
Mobilicom Limited announced a significant design win and initial order with a leading Tier-1 Israeli defense company to provide its cutting-edge SkyHopper MultiBand and Tactical solutions for a next-generation loitering munition platform. The selection follows successful field tests demonstrating superior connectivity and electronic warfare resista…
TransUnion's recent research highlights a confidence-readiness paradox among marketers investing in AI: while the majority are confident AI will transform marketing, many lack the foundational people, data, and process capabilities to fully realize AI's potential beyond efficiency gains. The study emphasizes data fragmentation as a key barrier affe…
Vishay Intertechnology, a leading manufacturer of discrete semiconductors and passive components, announced its Q2 2026 financial results showing a sequential revenue growth of 9.5% to $918.6 million (adjusted), surpassing the high end of guidance. The company reported a 23.3% GAAP gross margin and a diluted EPS of $0.19. Vishay's book-to-bill rati…
Gilat Satellite Networks Ltd. reported robust second quarter 2026 financial results with revenues increasing 17% to $122.7 million and adjusted EBITDA growing 31% to $15.4 million. The company reiterated its 2026 financial guidance projecting continued revenue and EBITDA growth. Progress on the acquisition of Comtech's Satellite & Space Communicati…
Lifecore Biomedical reported its Q2 2026 financial results, showing a slight revenue decrease compared to prior year periods. The company added multiple new late-stage programs to its pipeline, emphasized ongoing cost reduction and productivity improvements, and reaffirmed full-year 2026 revenue and Adjusted EBITDA guidance. Despite current losses,…
Fennec Pharmaceuticals, a specialty pharmaceutical company focused on reducing ototoxicity in cancer patients treated with cisplatin chemotherapy, will release its second quarter 2026 financial results on August 11, 2026, before U.S. market open. The company will host a conference call and webcast to discuss results. Fennec commercializes PEDMARK®,…
Lexeo Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020, its investigational gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy. This designation, along with prior Orphan Drug and Fast Track statuses, highlights promising interim clinical data from the ongoing Phase I/II HEROIC-PKP2…
Advantage Solutions Inc. reported Q2 2026 revenues of $889.5 million, a 1.8% increase year-over-year, driven primarily by growth in Experiential Services and slight growth in Retailer Services while Branded Services declined. Despite higher revenue, net loss widened to $62.7 million and Adjusted EBITDA dropped 12.2% to $75.8 million. The company re…
TeraWulf reported second quarter 2026 results highlighting revenue growth with 102 MW of revenue-generating capacity at Lake Mariner and 336 MW under construction. The company secured a landmark 20-year, approximately $19 billion lease with Anthropic at its Kentucky Justified Data Campus and acquired the gigawatt-scale Muskie Data Campus. TeraWulf …
Astec Industries, Inc. reported its second quarter 2026 financial results with net sales rising 23.6% to $408.1 million and backlog increasing nearly 58%. Despite growth in Materials Solutions, delays in Infrastructure Solutions asphalt plant shipments caused a reduction in full-year adjusted EBITDA guidance from $170-$190 million to $160-$175 mill…
Atea Pharmaceuticals, a late-stage biopharmaceutical company developing oral antivirals for serious viral diseases, announced its Q2 2026 financial results call scheduled for August 12, 2026. The company continues to progress its Phase 3 hepatitis C program and Phase 1 hepatitis E study, sharing updates with investors.
Telix Pharmaceuticals Limited will host an R&D Day event in New York City on September 22, 2026, providing investors and analysts with a comprehensive update on its therapeutic and precision medicine pipeline. The event will feature presentations from company leadership and key opinion leaders, highlighting clinical, scientific, and strategic devel…
Hennessy Capital Investment Corp. VII (NASDAQ: HVII) and ONE Nuclear Energy LLC announced that the SEC has declared effective their registration statement, enabling a shareholder meeting on August 24, 2026, to approve their proposed business combination. Upon closing, ONE Nuclear Energy Inc. will become a publicly traded company on NASDAQ under the…
J & J Snack Foods Corp. reported its fiscal 2026 third quarter results with a 6.2% decline in net sales to $426 million, impacted mainly by reduced bakery and frozen beverage machine sales. Despite lower sales, gross profit rose slightly and gross margin expanded by 240 basis points to 35.5%, attributed to operational efficiencies under the Apollo …
Royalty Pharma plc announced robust second quarter 2026 results with 14% growth in Royalty Receipts to $768 million and an overall 6% increase in Portfolio Receipts to $773 million. The company raised its full-year 2026 portfolio receipts guidance to $3.4 to $3.5 billion driven by strong performance of key products and active investments in new roy…
Kaltura, Inc. announced strong second quarter 2026 results, surpassing revenue and adjusted EBITDA guidance. Subscription revenue grew 8% year-over-year to $45.6 million, with total revenue at $46.9 million. The company achieved record non-GAAP gross margin of 75% and its highest Q2 adjusted EBITDA to date at $5.9 million. Kaltura signed a record f…
